[go: up one dir, main page]

NO20063516L - Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den - Google Patents

Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den

Info

Publication number
NO20063516L
NO20063516L NO20063516A NO20063516A NO20063516L NO 20063516 L NO20063516 L NO 20063516L NO 20063516 A NO20063516 A NO 20063516A NO 20063516 A NO20063516 A NO 20063516A NO 20063516 L NO20063516 L NO 20063516L
Authority
NO
Norway
Prior art keywords
crystalline form
agomelatine
preparation
form iii
pharmaceutical compositions
Prior art date
Application number
NO20063516A
Other languages
English (en)
Other versions
NO337010B1 (no
Inventor
Jean-Claude Souvie
Gerard Coquerel
Julie Linol
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20063516L publication Critical patent/NO20063516L/no
Publication of NO337010B1 publication Critical patent/NO337010B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Krystallinsk form III av forbindelsen med formel (l): karakterisert ved dens pulverrøntgendiffraksjonsdiagram. Medikamenter.
NO20063516A 2005-08-03 2006-08-02 Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den NO337010B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508276A FR2889521B1 (fr) 2005-08-03 2005-08-03 Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
NO20063516L true NO20063516L (no) 2007-02-05
NO337010B1 NO337010B1 (no) 2015-12-21

Family

ID=36587257

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063516A NO337010B1 (no) 2005-08-03 2006-08-02 Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den

Country Status (36)

Country Link
EP (3) EP2210872B1 (no)
JP (1) JP4580370B2 (no)
CN (1) CN100450995C (no)
AR (1) AR057713A1 (no)
AU (1) AU2006203336B2 (no)
BR (1) BRPI0603074A (no)
CA (1) CA2555117A1 (no)
CY (1) CY1118637T1 (no)
DK (1) DK2210872T3 (no)
EA (1) EA011031B1 (no)
ES (1) ES2614934T3 (no)
FR (1) FR2889521B1 (no)
GE (1) GEP20094576B (no)
GT (1) GT200600347A (no)
HK (1) HK1098130A1 (no)
HR (1) HRP20170095T1 (no)
HU (1) HUE030506T2 (no)
JO (1) JO3360B1 (no)
LT (1) LT2210872T (no)
MA (1) MA28449B1 (no)
ME (1) ME02689B (no)
MX (1) MXPA06008790A (no)
MY (1) MY142856A (no)
NO (1) NO337010B1 (no)
NZ (1) NZ548862A (no)
PE (1) PE20070213A1 (no)
PL (1) PL2210872T3 (no)
PT (1) PT2210872T (no)
RS (1) RS55499B1 (no)
SA (1) SA06270253B1 (no)
SG (1) SG130112A1 (no)
SI (1) SI2210872T1 (no)
TW (1) TWI389873B (no)
UA (1) UA83719C2 (no)
WO (1) WO2007015003A2 (no)
ZA (1) ZA200606454B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934856B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede d'obtention de la forme cristalline v de l'agomelatine
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102050755B (zh) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的晶型及其制备方法
CN101709036B (zh) * 2009-12-17 2012-07-04 天津药物研究院 阿戈美拉汀中间体2-(7-甲氧基-1-萘基)乙胺的制备
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101774937B (zh) * 2010-02-05 2014-01-08 天津市汉康医药生物技术有限公司 N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺及其组合物
EP2580183B1 (en) 2010-06-10 2014-07-23 Gador S.A. New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide
CZ303787B6 (cs) * 2011-01-21 2013-05-02 Zentiva, K.S. Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013082302A1 (en) 2011-11-30 2013-06-06 Ratiopharm Gmbh Agomelatine-urea complex and crystalline forms thereof
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
WO2014096373A1 (en) 2012-12-21 2014-06-26 Laboratorios Lesvi, S. L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2810656B1 (en) 2013-06-06 2017-08-02 Zentiva, a.s. Agomelatine formulations comprising agomelatine in the form of co-crystals
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
ES2959460T3 (es) 2015-03-31 2024-02-26 Fis Fabbrica Italiana Sintetici Spa Forma sólida de agomelatina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866336B1 (fr) * 2004-02-13 2006-03-24 Servier Lab Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine

Also Published As

Publication number Publication date
RS55499B1 (sr) 2017-05-31
SG130112A1 (en) 2007-03-20
CN1907959A (zh) 2007-02-07
MA28449B1 (fr) 2007-03-01
FR2889521B1 (fr) 2007-12-28
SI2210872T1 (sl) 2017-03-31
HRP20170095T1 (hr) 2017-03-24
AR057713A1 (es) 2007-12-12
EP1752445A1 (fr) 2007-02-14
LT2210872T (lt) 2017-01-10
MY142856A (en) 2011-01-14
EA200601274A1 (ru) 2007-02-27
EP2210872A1 (fr) 2010-07-28
WO2007015003A2 (fr) 2007-02-08
NZ548862A (en) 2008-03-28
PE20070213A1 (es) 2007-05-06
BRPI0603074A (pt) 2007-08-14
SA06270253B1 (ar) 2011-05-14
FR2889521A1 (fr) 2007-02-09
PT2210872T (pt) 2016-12-01
TWI389873B (zh) 2013-03-21
ZA200606454B (en) 2007-12-27
JO3360B1 (ar) 2019-03-13
EA011031B1 (ru) 2008-12-30
PL2210872T3 (pl) 2017-07-31
EP2008993A1 (fr) 2008-12-31
CN100450995C (zh) 2009-01-14
ME02689B (me) 2017-10-20
CY1118637T1 (el) 2017-07-12
GEP20094576B (en) 2009-01-12
ES2614934T3 (es) 2017-06-02
HK1098130A1 (en) 2007-07-13
TW200736197A (en) 2007-10-01
JP4580370B2 (ja) 2010-11-10
AU2006203336B2 (en) 2012-07-12
HUE030506T2 (en) 2017-05-29
AU2006203336A1 (en) 2007-02-22
JP2007051140A (ja) 2007-03-01
DK2210872T3 (en) 2017-02-20
NO337010B1 (no) 2015-12-21
UA83719C2 (ru) 2008-08-11
EP2210872B1 (fr) 2016-11-16
WO2007015003A3 (fr) 2007-04-05
CA2555117A1 (fr) 2007-02-03
GT200600347A (es) 2007-02-28
MXPA06008790A (es) 2008-02-04

Similar Documents

Publication Publication Date Title
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063516L (no) Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063518L (no) Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20064596L (no) Delta-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060949L (no) yd-krystallinsk form avivabradin-hydroklorid, fremgangsmate for dens frem5l1lling 0g farmasoytiske sammensetninger inneholdende den
NO20060948L (no) Á-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060947L (no) β d-krystalinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060946L (no) β-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20064588L (no) Delta d-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende den
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
MY151035A (en) ? crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
NO20052998L (no) Alfa krystallinsk form av strontiumranelat, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den.
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
MY138209A (en) New (y) crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it.
TNSN05076A1 (en) New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
GEP20094652B (en) New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TNSN05077A1 (en) New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
TNSN05078A1 (en) New beta crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees